Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field May 31, 2023
IDEAYA Expands Clinical Trial Collaboration and Supply Agreements with Pfizer to Support Registrational Trial Evaluating Darovasertib and Crizotinib Combination in First-Line Metastatic Uveal Melanoma May 31, 2023
KSQ Therapeutics And Takeda Expand Strategic Immuno-Oncology Collaboration To Identify And Validate Novel Tumor Targets May 31, 2023
Enrollment completed in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer May 31, 2023
Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients May 31, 2023
Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1L NSCLC May 31, 2023
Promising New Clinical Data Announced from Triple Combination Therapy in INSIGHT-003 Trial May 31, 2023
Update of Ongoing Ph 1 Study of Voruciclib +/- Venetoclax in Patients with AML or B-Cell Malignancies Announced May 31, 2023
FAILED TRIAL: Ph 3 SAPPHIRE study of sitravatinib + (OPDIVO) vs docetaxel in patients with 2/3L advanced NSQ-NSCLC did not meet primary endpoint of OS May 31, 2023
KEYTRUDA + LENVIMA Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as 1L Treatment for Patients With Advanced RCC May 31, 2023
TAGRISSO + chemo demonstrated strong improvement in PFS for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial May 31, 2023
IMFINZI + LYNPARZA and IMFINZI alone both significantly improved PFS in advanced endometrial cancer when added to chemotherapy May 31, 2023
Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer May 31, 2023
Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers May 31, 2023
Type II variation application to EMA submitted for a new indication for CARVYKTI in adult patients with relapsed and lenalidomide-refractory multiple myeloma May 31, 2023
Positive CHMP Opinion to Opdivo + Chemo as Neoadjuvant Treatment of Resectable NSCLC at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression May 31, 2023
NDA for Fruquintinib for Treatment of Previously Treated mCRC Granted Priority Review; PDUFA: Nov 2023 May 31, 2023
